Search Thermo Fisher Scientific
Benefits of Targeted NGS for Cancer Research
Get more from your tumor sample with next-generation sequencing
With next-generation sequencing (NGS) you can get more results, more quickly in a single test. Traditional genetic testing methods involve the use of single gene tests performed in succession to determine the presence or absence of variants of interest. Because of the sample size requirements for running each of these tests and the number of tests required to narrow in on the right answer, sequential testing can often lead to inconclusive results. Additionally, sequential testing can be laborious and expensive, requiring many days or weeks of work before finding the right answer.
Alternatively, with NGS you can simultaneously search for variants of interest using a single sample in a single experiment. You can see SNPs, indels, CNVs, gene fusions, and expression results in a single run. And with the Ion PGM System and Ion AmpliSeq technology you only need 10 ng of sample to obtain these results.
Already cancer researchers using NGS have contributed to an explosion in genetic information that has helped to elucidate the effects of mutations in many cancer genes at a functional level.
"With gene panel sequencing on the Ion PGM System of the Ion AmpliSeq Colon & Lung Cancer Panel, we are able to detect the changes in tens of genes at once, not just the particular mutations that you happen to be looking for in a few hotspot regions."
Ian Cree, MD, PhD
Professor of Pathology
The University of Warwick Coventry,
United Kingdom
OncoNetwork Consortia
For Research Use Only. Not for use in diagnostic procedures.